Dabigatran is a direct thrombin inhibitor, which is increasingly likely to be encountered in patients presenting for surgery. This study examines whether there is a consistent effect of dabigatran on the thromboelastogram (TEG) and whether this correlates with the effects of dabigatran on traditional coagulation parameters. Twenty patients taking dabigatran had blood sampled for kaolin-activated whole blood TEG analysis and routine coagulation testing. There was a statistically significant correlation between thrombin clotting time (TCT) and R-time (R=0.77, P=0.0001) and between activated partial thromboplastin time (APTT) and R-time (R=0.68, P=0.0013), but not between TCT and alpha-angle (R= -0.4232, P=0.071).
Introduction
Dabigatran is an oral direct thrombin inhibitor that is licenced for use in the prevention of stroke in patients with non-valvular atrial fibrillation (AF) and for thromboprophylaxis following orthopaedic surgery. It has been associated with similar or lower rates of major haemorrhage than warfarin in the treatment of patients with AF 1 . Dabigatran has predictable pharmacodynamics and kinetics 2, 3 , therefore routine monitoring is not required. There is also no current test of coagulation that can predict the bleeding risk related to the administration of dabigatran. Of the traditional tests, thrombin clotting time (TCT) is the most sensitive. International Normalized Ratio (INR) and activated partial thromboplastin time (APTT) can detect the presence of dabigatran but are insensitive and often are normal despite therapeutic levels of dabigatran 4, 5 . In combination these tests can identify the presence of dabigatran and may give a rough estimate as to low or very high plasma levels, but they do not give a true indication of the actual degree of anticoagulation and risk of abnormal bleeding.
Encountering patients who have been taking dabigatran prior to surgery is becoming common in clinical practice. Two scenarios that are representative of the problems posed by these patients are the acute patient where surgery cannot be delayed, where assessing the degree of dabigatran effect present will help guide management; and the semi-acute patient, where assessment of the offset of dabigatran effect determines when surgery can proceed.
The thromboelastogram (TEG) is a point-of-care test that assesses several parameters of the clotting cascade. It is widely available in theatre situations and has been shown to reduce blood product usage when used as part of a blood management algorithm in cardiac surgery 6 . Given thrombin's position in the coagulation cascade it is plausible that the TEG will reflect the effect of dabigatran on coagulation. It would be expected that dabigatran should delay the R-time (reaction time, time to first evidence of a clot) and decrease the alpha-angle (representing the speed of clot formation) of the TEG.
Our primary hypothesis was that the TEG R-time correlates with the TCT in ex vivo blood samples. Our secondary hypotheses were that the alpha-angle correlates with the TCT and that R-time correlates with the APTT. We did not aim to assess the ability of the TEG to assess bleeding risk in patients.
Materials and methods
Ethics approval was obtained from the institutional research board at Waikato District Health Board (RD015008). Written consent was obtained from all participants. Twenty inpatients taking dabigatran for non-valvular AF underwent blood sampling. The samples were analysed immediately with kaolin activation using the TEG 5000® Thromboelastograph® Hemostasis Analyzer system (Haemonetics Corporation, Braintree, MA, USA). An additional sample was taken at the same time for INR, APTT, TCT and fibrinogen.
Inclusion in the study required each patient to be taking dabigatran but no other form of anticoagulation. Compliance with taking dabigatran was confirmed verbally with the patient and verified by the patient's inpatient prescription drug chart, which is countersigned by the nurse administering the medication with a time and date of administration.
Venous blood was sampled at no specific time after the last oral dose. Nineteen of 20 samples were taken by the same person; a tourniquet was applied to the upper limb and a 10 ml syringe with an 18G needle was used to take the blood sample. Four and a half millilitres was then aspirated into a heparinised Vacutainer for the laboratory coagulation tests. The remaining blood was used for TEG analysis within four minutes of sampling.
The laboratory in our institution conducts the APTT testing using the Tcoag Triniclot™ HS (Tcoag, Co. Wicklow, Ireland) APTT reagent, which contains micronised silica as the activator, and a porcine and galline (chicken-derived) phospholipid component with a preservative. Following that calcium chloride is added to initiate the clotting reaction. The TEG was run by one of six trained anaesthetic technicians who routinely use the TEG machine for analysis of coagulation for all cardiac surgical patients. In our institution over 2000 TEGs are run by these technicians per annum. All four TEG machines had daily electronic testing and weekly level one and level two quality control checks involving re-checking the calibration.
For each TEG one ml of uncitrated whole blood is pipetted into a cartridge with a predetermined amount of kaolin for activation of the sample. All TEGs were run for a minimum of 30 minutes, which enabled them to pass their maximum amplitude and to display any potential fibrinolysis.
The TEG variables recorded were the R-time reflecting the initiation phase of coagulation related to the function of clotting factors, alpha-angle which denotes the rate at which the clot is strengthening and which represents thrombin's cleaving of the available fibrinogen to fibrin, and the maximum amplitude representing maximal clot strength.
A Kolmogorov-Smirnov test was applied to all data to test for normalcy. Parametric data were described in terms of mean and standard deviation. Non-parametric data was described in terms of median and range. All data for comparison via correlation included at least one variable that was non-parametric, so the Spearman correlation coefficient was used to test the correlation between the variables of interest.
Results
Demographics for the 20 patients are presented in Table 1 . The traditional coagulation test results and the TEG variables are shown in Table 2 . Data for the conventional coagulation tests was missing for one patient due to sampling error. All patients had an elevated TCT (>45 seconds, normal <20 seconds). Five patients had a TCT over 150 seconds, five had values between 100-150 seconds, and eight had values between 50 and 100 seconds. One patient had a value between 45 and 50 seconds.
Six patients had a normal APTT, eight patients had a value of 1 to 1.5 times normal and five patients had a value greater than 1.5 times normal, with the highest value being 2.2 times normal. INR ranged between 1.0 and 1.9. Eleven patients had an INR in the normal range (0.8-1.2). Six patients had an INR of 1.3-1.5, and two patients had an INR over 1.5.
Seven patients had a normal R-time, nine patients had an R-time of 9-13 minutes (1-1.5 times normal), and four patients had an R-time over 13 minutes (over 1.5 times normal). Ten patients had a normal maximum amplitude (MA, 55-74 mm) and ten patients had an MA above 74 mm. Sixteen patients had a normal alpha-angle (59-74), three patients had a reduced alpha-angle, and one patient had an increased alpha-angle.
The MA, TCT, APTT and fibrinogen were all normally distributed. The alpha-angle, R-time and INR were not normally distributed.
The Spearman correlation coefficient between R-time and TCT was 0.77 (P=0.0001, R 2 = 0.59, Figure 1 ). The Spearman correlation coefficient between alpha-angle and TCT was -0.4232 (P=0.071, Figure 2 , R 2 =0.18). The Spearman correlation coefficient between R-time and APTT was 0.68 (P=0.0001, R 2 = 0.47, Figure 3 ).
Discussion
This study shows that there is a statistically significant correlation between the R-time and the TCT, and between the R-time and the APTT. This indicates that the anticoagulant effects of dabigatran are detectable on the TEG. Our study differed from previous studies where the effect of dabigatran on the TEG was assessed in vitro 7, 8 or in healthy volunteers 9 . Therefore our study closely resembles actual in vivo conditions. Nevertheless, the question that arises is whether the relationship between R-time and TCT is robust enough to enable clinical decisions to be made on the basis of the TEG.
The R 2 value gives us an indication of how much of the variability seen is due to the relationship between the two variables. In this case, just over half the variability seen is due to the underlying relationship between R-time and TCT. This means that almost half the variability is not explained by the relationship between R-time and TCT. Clearly, this means that R-time is not sensitive enough to base clinical decisions, such as whether to proceed with surgery or whether it is safe to perform a neuraxial block. This limitation is supported by the observations in seven patients who had R-times within the normal range despite elevated TCT.
Anyone familiar with a TEG tracing can identify the effect of heparin on the TEG, as there is a reliably prolonged R-time. We were expecting that dabigatran would produce a similarly reliable effect on the TEG; however this was not the case.
Most guidelines would suggest that TCT should have returned to normal prior to proceeding to surgery that has a high risk of bleeding or before performing a neuraxial technique. This is by necessity a conservative guideline. It is possible that TEG provides a better guide than TCT as to the effect of dabigatran on coagulation and the true risk of abnormal bleeding. However, it is difficult to see how this hypothesis could be tested, as proceeding to surgery at high risk of bleeding in the situation of increased TCT but normal TEG is probably not defensible outside the emergency setting when no alternatives are available.
Previous studies have taken blood samples from volunteers and spiked them with a known concentration of dabigatran and studied the effects on the TEG at different concentrations of dabigatran 7, 8 . In this manner they achieved reliable effects on the TEG with very narrow confidence intervals of their TEG-related variables (e.g. R-time). Our findings suggest that this is not the case when translated to the clinical setting. There are two possible explanations for this result. It is possible that there is a very wide spread of plasma levels that are achieved with dabigatran dosing, and there is certainly literature that would suggest that there is significant interpatient variation in the plasma levels that are achieved with a given dose 5, 10 . Thus the wide variety of dabigatran levels may partially explain why there was such a wide spread of R-times in the study population. Another possible explanation is that there are other in vivo changes that occur in a patient's coagulation system that affect the shape of the TEG tracing. It seemed as though the patients in our cohort tended to have a high fibrinogen, with 12 out of 19 patients having a fibrinogen level above normal.
The contribution of the variation in dabigatran plasma levels to the results of this study would have been confirmed by the measurement of dabigatran plasma levels. This is one of the weaknesses of this study. However, plasma levels are expensive to undertake and are not available in every institution, and therefore our study reflects the accessibility to coagulation tests in most clinical settings. In addition, there is no current evidence predicting the likelihood of abnormal bleeding with a given dabigatran level. This means that clinical decisions cannot currently be made on the dabigatran plasma level. Previous case report data would suggest that significant bleeding may occur with a plasma level as low as 23 ng/ml 11, 12 , although the case report data comes from cardiac surgical cases where there are multiple reasons for postoperative bleeding.
It should be emphasised that this study relates only to kaolin-activated uncitrated whole blood TEG and our results may not be applicable to other forms of TEG or modified TEG. In fact, there have been recent developments using a thrombin generation assay in combination with TEG, using ecarin instead of kaolin, that promise a significantly improved ability of the TEG to detect the effect of dabigatran 13, 14 . However, these reports have at this stage been published only in abstract form, so it is difficult to assess the potential efficacy of these methods. Our results also do not necessarily apply to ROTEM® techniques.
In conclusion, in this study we found a statistically significant correlation between the kaolin-activated whole blood TEG R-time and both the TCT and the APTT ex vivo. This indicates that TEG detects the effect of dabigatran. However, despite these moderate to high correlations, there appeared to be no consistent effect of dabigatran on the TEG. These findings suggest that use of the kaolin-activated whole blood TEG does not add additional benefit to traditional coagulation tests when monitoring the effect of dabigatran.
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